Literature DB >> 9988401

Withholding gonadotropins ("coasting") to minimize the risk of ovarian hyperstimulation during superovulation and in vitro fertilization-embryo transfer cycles.

M R Fluker1, W M Hooper, A A Yuzpe.   

Abstract

OBJECTIVE: To evaluate superovulation (SOV) and IVF-ET cycles in which E2 levels were allowed to decrease to restrain rapid follicular growth and minimize the risk of ovarian hyperstimulation syndrome.
DESIGN: Retrospective series.
SETTING: Tertiary care infertility practice. PATIENT(S): Women who underwent SOV (n = 51) and IVF-ET (n = 93) treatment and who were at risk for OHSS. INTERVENTION(S): In SOV cycles, hMG was withheld (coasting) for >3 days before hCG administration, until follicular maturity was attained (> or = 3 follicles of > or = 18 mm) and E2 levels decreased. In IVF-ET cycles, either follicular maturity was attained before coasting (n = 63), allowing hCG administration after E2 levels decreased by >25%, or coasting occurred before follicular maturation (n = 30), necessitating the administration of additional hMG after coasting. MAIN OUTCOME MEASURE(S): Estradiol concentrations, follicle size, and pregnancy rates. RESULT(S): Estradiol concentrations usually rose for > or = 1 day after coasting began, then fell by > or = 25% while follicle numbers and mean diameters increased. No spontaneous LH surges occurred, although four SOV cycles were canceled because of excessive follicular development. Of the women who received hCG,11 of 47 (23% per cycle) conceived during SOV and 35 of 93 (37.6% per cycle) conceived during IVF-ET. Severe ovarian hyperstimulation syndrome developed in 1 woman who underwent IVF-ET. CONCLUSION(S): Coasting can safely rescue overstimulated SOV and IVF-ET cycles characterized by an excessive rise in E2 levels and/or numerous incompletely mature follicles.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9988401     DOI: 10.1016/s0015-0282(98)00438-5

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  7 in total

1.  Is Coasting Valuable in All Patients with Any Cause of Infertility?

Authors:  Tahereh Madani; Nadia Jahangiri; Poopak Eftekhari-Yazdi; Mahnaz Ashrafi; Mohammadreza Akhoond
Journal:  Oman Med J       Date:  2016-11

Review 2.  Safety of drugs used in assisted reproduction techniques.

Authors:  Talha Al-Shawaf; Ariel Zosmer; Martha Dirnfeld; Gedis Grudzinskas
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Estradiol level on day 9 as a predictor of risk for ovarian hyperresponse during controlled ovarian hyperstimulation.

Authors:  Hsin-Yi Ho; Robert Kuo-Kuang Lee; Ming-Huei Lin; Yuh-Ming Hwu
Journal:  J Assist Reprod Genet       Date:  2003-06       Impact factor: 3.412

Review 4.  Contemporary pharmacological manipulation in assisted reproduction.

Authors:  Judith A F Huirne; Cornelis B Lambalk; Andre C D van Loenen; Roel Schats; Peter G A Hompes; Bart C J M Fauser; Nick S Macklon
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Serum FSH Levels in Coasting Programmes on the hCG Day and Their Clinical Outcomes in IVF ± ICSI Cycles.

Authors:  Srisailesh Vitthala; Jerome Bouaziz; Amanda Tozer; Ariel Zosmer; Talha Al-Shawaf
Journal:  Int J Endocrinol       Date:  2012-02-12       Impact factor: 3.257

6.  Luteinizing hormone changes in gonadotropin-releasing hormone antagonist protocol in in vitro fertilization cycles: A cross-sectional study.

Authors:  Batool Hosein Rashidi; Roya Kabodmehri; Mamak Shariat; Ensieh Shahrokh Tehraninejad; Alireza Abdollahi; Maryam Bagheri; Fedieh Hagholahi
Journal:  Int J Reprod Biomed       Date:  2019-05-05

7.  GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial.

Authors:  Usama M Fouda; Ahmed M Sayed; Hesham S Elshaer; Bahaa Eldin M Hammad; Mona M Shaban; Khaled A Elsetohy; Mohamed A Youssef
Journal:  J Ovarian Res       Date:  2016-05-17       Impact factor: 4.234

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.